October 20, 2026

Nationwide Recall of Compounded GLP-1 Injections Due to Sterility Concerns

Compounded GLP-1 injections made by a pharmacy with a previous FDA warning have been recalled nationwide. Apothecary Pharma LLC first started a voluntary recall of tirzepatide injections on September 24 due to ‘lack of assurance of sterility,’ according to an FDA notice. The recall was classified as ‘Class II’ on October 10, indicating that using the medication might cause ‘temporary or medically reversible adverse health consequences,’ though the risk of serious harm is minimal.

Details of the Recall

The injections are compounded GLP-1 versions and are not brand-name or FDA-approved. They were formulated by Apothecary Pharma, a specialized compounding pharmacy. Past concerns about sterility and sanitation have been an issue for compounding pharmacy injections, exemplified by a 2012 fungal meningitis outbreak that resulted in 64 deaths from unsanitary injections by New England Compounding Center.

The FDA has focused on compounded GLP-1s since tirzepatide and semaglutide were removed from the drug shortage list in late 2024 and early 2025. Compounding pharmacies, which filled this gap for millions, have continued production. This led to FDA warnings and legal challenges. A 2025 letter warned Apothecary Pharma of ‘serious deficiencies’ in sterile drug production practices.

Compounded GLP-1 Injections Recalled

A total of 22 vials of tirzepatide were recalled across the nation. The recalled Apothecary Pharma Tirzepatide Injection bottles include:

  • 18mg/mL, 4 mL sterile multi-dose vial, Prescription only
  • Lot Codes and Beyond Use Dates:
    • AP-202622, BUD 07-Oct-2026
    • AP-202623, BUD 08-Oct-2026
    • AP-202624, BUD 19-Oct-2026
    • AP-202625, BUD 20-Oct-2026
    • AP-202627, BUD 26-Oct-2026
    • AP-202628, BUD 27-Oct-2026
    • AP-202629, BUD 28-Oct-2026
    • AP-202630, BUD 31-Oct-2026
    • AP-202631, BUD 01-Nov-2026
    • AP-202632, BUD 03-Nov-2026
    • AP-202633, BUD 07-Nov-2026
    • AP-202634, BUD 08-Nov-2026
    • AP-202635, BUD 16-Nov-2026
    • AP-202636, BUD 17-Nov-2026
    • AP-202637, BUD 18-Nov-2026
    • AP-202638, BUD 19-Nov-2026
    • AP-202639, BUD 20-Nov-2026
    • AP-202640, BUD 21-Nov-2026
    • AP-202641, BUD 22-Nov-2026
    • AP-202642, BUD 24-Nov-2026
    • AP-202643, BUD 25-Nov-2026
    • AP-202644, BUD 26-Nov-2026

Guidance for Affected Users

Neither the FDA nor Apothecary has issued specific public instructions for handling affected vials. Customers have noted that some prescribers are asking for returns or disposals. If you possess an affected lot, avoid using it and contact your healthcare provider for guidance.

Understanding Compounding Pharmacies

Compounding pharmacies create custom drug versions from raw ingredients. They have gained attention with the rise of GLP-1s and peptides. Unlike commercial pharmacies selling mass-produced drugs, these pharmacies customize dosages or remove allergens. They also offer solutions during drug shortages, such as the 2022 FDA authorization allowing compounders to produce GLP-1 medications mid-shortage. Even after tirzepatide and semaglutide were delisted for shortages, some compounders continued producing and selling them widely, particularly through telehealth.

Compounding pharmacies use FDA-approved ingredients, but their formulations lack FDA evaluation for purity, safety, or effectiveness. They are not routinely regulated, leading to sanitation problems, such as a tragic 2012 outbreak or reports of unapproved ingredient use in 2023. Pharmaceutical companies like Eli Lilly and Novo Nordisk have filed lawsuits to curb these practices.

To check a pharmacy’s reliability, visit the Alliance for Pharmacy Compounding website and consult your doctor.

TAGS: